Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

550
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
550
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

15.2K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
15.2K
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

4.5K
4.5K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

615
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
615
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

11.0K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

18.8K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
18.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Short-term effects of exercise therapy on pulmonary function and exercise tolerance in patients with mild to moderate adolescent idiopathic scoliosis: a meta-analysis of randomized controlled trial.

Frontiers in sports and active living·2026
Same author

Hypoxia increases susceptibility of grass carp to Aeromonas hydrophila infection by inducing oxidative stress and impairing antimicrobial defense.

Fish & shellfish immunology·2026
Same author

Global Landscape and Translational Trajectories of Pelvic Floor Muscle Rehabilitation for Urinary Incontinence.

International urogynecology journal·2026
Same author

Putative buffering roles of two-way social support and psychological resilience in the association between nurse-patient conflict and situational emotional response: a cross-sectional correlational study among Chinese nursing interns.

BMC nursing·2026
Same author

Immunomodulatory and Gut Microbiota-Regulating Effects of Lactobacillus helveticus LH76 in Healthy Adults: Preclinical Safety Assessment and a Randomized, Double-Blind, Placebo-Controlled Trial.

Probiotics and antimicrobial proteins·2026
Same author

Engineering Crystalline Frameworks into Porous Liquids to Fabricate Graphene Oxide/Porous Liquid Membranes for Efficient Li<sup>+</sup>/Mg<sup>2+</sup> Separation.

Nature communications·2026

Related Experiment Video

Updated: Feb 7, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K

Advances in Janus Kinase Inhibitors for Vitiligo Treatment.

Wanlin Wang1, Yue Liao1, Ruizhi Zhang2

  • 1Sino-French Hoffmann Institute, School of Basic Medical Sciences, The Second Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, Guangdong Provincial Key Laboratory of Allergy & Clinical Immunology, Guangzhou Medical University, Guangzhou, China.

Drug Research
|February 5, 2026
PubMed
Summary

Vitiligo, an autoimmune skin condition, involves melanocyte destruction. Janus kinase (JAK) inhibitors show promise for treating vitiligo by targeting key signaling pathways involved in the disease.

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.3K
Protein Kinase C-delta Inhibitor Peptide Formulation using Gold Nanoparticles
06:06

Protein Kinase C-delta Inhibitor Peptide Formulation using Gold Nanoparticles

Published on: March 9, 2019

5.9K

Related Experiment Videos

Last Updated: Feb 7, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.3K
Protein Kinase C-delta Inhibitor Peptide Formulation using Gold Nanoparticles
06:06

Protein Kinase C-delta Inhibitor Peptide Formulation using Gold Nanoparticles

Published on: March 9, 2019

5.9K

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Vitiligo is an autoimmune disease causing melanocyte destruction and depigmentation.
  • Affects 0.5-2% globally, significantly impacting quality of life.
  • Pathogenesis involves cytokines acting via the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway.

Purpose of the Study:

  • To review vitiligo pathogenesis at cellular, molecular, and genetic levels.
  • To elucidate the role of the JAK/STAT pathway in vitiligo.
  • To summarize current and preclinical JAK inhibitors for vitiligo treatment.

Main Methods:

  • Literature review of vitiligo pathogenesis.
  • Analysis of JAK/STAT pathway involvement.
  • Summary of approved and investigational JAK inhibitors.

Main Results:

  • JAK/STAT pathway is central to vitiligo pathogenesis.
  • Newer selective JAK inhibitors offer improved safety and efficacy.
  • Several JAK inhibitors are in clinical trials for vitiligo.

Conclusions:

  • Targeting the JAK/STAT pathway is a viable therapeutic strategy for vitiligo.
  • Selective JAK inhibitors represent a promising advancement in vitiligo treatment.
  • Ongoing research and clinical trials are advancing JAK inhibitor therapies for vitiligo.